Sarpogrelate treatment reduces restenosis after coronary stenting

Sarpogrelate treatment reduces restenosis after coronary stenting

Item
http://www.wikidata.org/entity/Q28195521
Q28171071
sameAs
Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim DatabaseEffect of sarpogrelate treatment on the prognosis after endovascular therapy for critical limb ischemia.Serotonin antagonism improves platelet inhibition in clopidogrel low-responders after coronary stent placement: an in vitro pilot study.The prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease: a study protocol for a prospective randomized controlled clinical trialSarpogrelate: cardiovascular and renal clinical potential.Pharmacological basis of different targets for the treatment of atherosclerosis.Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions: Preliminary ResultsAntiplatelet therapy attenuates subcellular remodelling in congestive heart failure.Clopidogrel in acute coronary syndrome: implications of recent study findings.Effectiveness of sarpogrelate after endovascular treatment for femoropopliteal artery disease: ESPALIER study.SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial.Pharmacokinetics of a new once-daily controlled-release sarpogrelate hydrochloride compared with immediate-release formulation and the effect of food.Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarction.Inhibition of 5-Hydroxytryptamine Receptor 2B Reduced Vascular Restenosis and Mitigated the β-Arrestin2-Mammalian Target of Rapamycin/p70S6K Pathway.Sarpogrelate, a 5-hT2A receptor antagonist in intermittent claudication. A phase II European study.Effect of the potent CYP2D6 inhibitor sarpogrelate on the pharmacokinetics and pharmacodynamics of metoprolol in healthy male Korean volunteers.
P2860

Sarpogrelate treatment reduces restenosis after coronary stenting

Item
http://www.wikidata.org/entity/Q28195521
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Sarpogrelate treatment reduces restenosis after coronary stenting
@ast
Sarpogrelate treatment reduces restenosis after coronary stenting
@en
Sarpogrelate treatment reduces restenosis after coronary stenting
@nl
type
label
Sarpogrelate treatment reduces restenosis after coronary stenting
@ast
Sarpogrelate treatment reduces restenosis after coronary stenting
@en
Sarpogrelate treatment reduces restenosis after coronary stenting
@nl
prefLabel
Sarpogrelate treatment reduces restenosis after coronary stenting
@ast
Sarpogrelate treatment reduces restenosis after coronary stenting
@en
Sarpogrelate treatment reduces restenosis after coronary stenting
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P698
P356
P1433
P1476
Sarpogrelate treatment reduces restenosis after coronary stenting
@en
P2093
P304
P31
P356
P407
P433
P478
P577
P698